AxoGen Inc. (AXGN)
19.01
0.21 (1.12%)
At close: Mar 27, 2025, 3:59 PM
18.29
-3.78%
After-hours: Mar 27, 2025, 07:55 PM EDT
1.12% (1D)
| Bid | 18.1 |
| Market Cap | 842.98M |
| Revenue (ttm) | 185.11M |
| Net Income (ttm) | -9.85M |
| EPS (ttm) | -0.23 |
| PE Ratio (ttm) | -82.65 |
| Forward PE | 60.16 |
| Analyst | Buy |
| Ask | 19.62 |
| Volume | 564,281 |
| Avg. Volume (20D) | 544,461 |
| Open | 18.91 |
| Previous Close | 18.80 |
| Day's Range | 18.67 - 19.33 |
| 52-Week Range | 5.55 - 21.00 |
| Beta | 1.02 |
About AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for te...
Industry Medical - Devices
Sector Healthcare
IPO Date Dec 17, 1986
Employees 451
Stock Exchange NASDAQ
Ticker Symbol AXGN
Website https://www.axogeninc.com
Analyst Forecast
According to 6 analyst ratings, the average rating for AXGN stock is "Buy." The 12-month stock price forecast is $26, which is an increase of 36.77% from the latest price.
Stock ForecastsNext Earnings Release
AxoGen Inc. is scheduled to release its earnings on May 1, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+11.66%
Axogen shares are trading higher after the company...
Unlock content with
Pro Subscription
4 months ago
-13.44%
Axogen shares are trading lower. The company reported Q3 financial results.
2 months ago · seekingalpha.com
Axogen: Well Placed To Capitalize Growth At Higher MultiplesAxogen: Well Placed To Capitalize Growth At Higher Multiples